Edition:
United States

Avenue Therapeutics Inc (ATXI.OQ)

ATXI.OQ on NASDAQ Stock Exchange Capital Market

4.15USD
23 Apr 2018
Change (% chg)

$-0.21 (-4.82%)
Prev Close
$4.36
Open
$4.35
Day's High
$4.35
Day's Low
$4.11
Volume
11,593
Avg. Vol
7,485
52-wk High
$8.56
52-wk Low
$3.40

Chart for

About

Avenue Therapeutics, Inc. is a pharmaceutical company. The Company is engaged in acquiring, licensing, developing and commercializing products principally for use in the acute or intensive care hospital setting. Its product candidate is intravenous (IV) Tramadol, an intravenous formulation of tramadol hydrochloride (HCl), for... (more)
No analyst recommendations are available for .

Overall

Beta: --
Market Cap(Mil.): $44.72
Shares Outstanding(Mil.): 10.28
Dividend: --
Yield (%): --

Financials

  ATXI.OQ Industry Sector
P/E (TTM): -- 30.21 32.78
EPS (TTM): -1.29 -- --
ROI: -186.32 13.61 13.21
ROE: -220.23 15.28 15.01

BRIEF-Avenue Therapeutics Reports Q4 Loss Per Share $0.63

* AVENUE THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS

Mar 01 2018

BRIEF-Avenue Therapeutics reports Q3 loss per share $0.30

* Avenue Therapeutics Inc reports third quarter 2017 financial results and recent corporate highlights

Nov 09 2017

Earnings vs. Estimates